Neosoma, Inc. — SEC Form D Filing
Neosoma, Inc. filed an SEC Form D on March 27, 2026, reporting $3.52M raised in Health Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- March 27, 2026
- Amount reported
- $3.52M
- Round stage
- Seed
- Industry
- Health Technology
- Website
- https://www.neosomainc.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Clinicians often struggle to accurately assess brain lesions due to the complexity and variability in interpretation. Misjudgments can impact patient care and treatment decisions.
Solution
Neosoma provides a cloud software platform that automates lesion mapping and assessment, allowing for accurate tracking and quantification over time. This helps clinicians make informed decisions quickly.
Why now
The growing prevalence of neuro-oncological disorders and the increasing complexity of medical imaging require advanced tools for effective diagnosis and treatment planning.
Verdict
Investors said yes to Neosoma at that moment because they recognized the necessity for technological advancement in an increasingly complex healthcare landscape, betting implicitly on a significant shift in the diagnostic capability of clinicians via automation. This cleared because the platform's promise of precision and efficiency resonated, not because the market lack of competition in health technology was evident. However, the upside is limited given the challenges of regulatory compliance and the potential for rapid obsolescence due to technological advancements from larger incumbents.
Source: SEC EDGAR Form D filing